Chinese biopharma stocks jumped Monday. Not because anything changed. Because a report suggested the U.S. might continue allowing what it already allows.
Read that twice. The market rallied on the news that a policy might remain exactly the same. Traders saw a headline that said "we're thinking about not doing a thing we weren't doing" and bought with both hands. This is the financial equivalent of your neighbor knocking on your door to tell you he's decided not to burn your house down. You weren't worried about it until he brought it up, but now you're supposed to feel grateful.
The stocks that popped hardest were the ones with the most U.S. licensing deals at risk. Except the deals were never at risk. The door was already open. The report just said it might stay open. So shareholders celebrated the absence of a threat that existed only in their heads, which is honestly the purest form of market psychology ever documented.
Retail traders piled in, naturally. They read "U.S. weighs keeping door open" and assumed that meant the door was closed. It wasn't. They bought the rumor of the absence of a restriction that never existed. Then they logged into their brokerage apps and saw their positions up four percent and felt like Warren Buffett.
The charts told you none of this mattered. Support held. Resistance held. The same levels that worked last month still worked. The same patterns that failed last year still failed. But every talking head on financial television spent the day explaining why this non-event was actually a pivotal geopolitical shift, as if the U.S. announcing it might not change its mind is somehow breaking news.
The door was open yesterday. It's open today. Tomorrow someone will write a report saying it might stay open, and the stocks will jump again. Pavlov would've loved these f*cking people.
Photo by on Unsplash
Leave a Comment